Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk's popular obesity drug Wegovy in a mid-stage ...

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...

Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to ...

The combination offers a potential solution to one of the key problems that’s emerged with popular obesity shots.

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

A new study finds combining bimagrumab with Wegovy leads to significant fat loss without muscle loss. This breakthrough ...

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting compared to clinical trials.

A protocol designed for primary care increased weight loss across a quarter ... from a 4-year study of the ... Ther, Novo Nordisk, PharmaVentures, Pfizer, Regeneron, Roche ...

When researchers analyzed weight loss results from patients who took GLP-1 drugs and those who'd undergone bariatric surgery, ...